Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy

Clinical Infectious Diseases

Volumn 59, Issue 12, 2014, Pages 1761-1767

  Grace, Eddie ^a   Turner, R Mackenzie ^b  

^a PRESBYTERIAN COLLEGE   (United States)

^b Bon Secours St Francis Hospital   (United States)

Author keywords

chronic kidney disease; dialysis; procalcitonin; renal replacement therapy; serological marker

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CHRONIC KIDNEY DISEASE; CONTINUOUS HEMODIALYSIS; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG USE; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPSIS; SEVERE RENAL IMPAIRMENT; ADVERSE EFFECTS; BLOOD; DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

CALCITONIN; DIALYSIS; HUMANS; PROTEIN PRECURSORS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84924977571     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu732     Document Type: Article

References (57)

1. Moya F, Nieto A, R-Candela JL. Calcitonin biosynthesis: evidence for a precursor. Eur J Biochem 1975; 55:407-13.
2. Jacobs JW, Lund PK, Potts JT, Bell NH, Habener JF. Procalcitonin is a glycoprotein. J Bio Chem 1981; 256:2803-7.
3. Allison J, Hall L, Macintyre I, Craig RK. The construction and partial characterization of plasmids containing complementary DNA sequences to human calcitonin precursor polyprotein. Biochem J 1981; 199:725-31.
4. Gkonos PJ, Born W, Jones BN, et al. Biosynthesis of calcitonin generelated peptide and calcitonin by a human medullary thyroid carcinoma cell line. J Biol Chem 1986; 261:14386-91.
5. Flanders KC, Birnbaum RS, Mahoney WC, Roos BA. Biosynthesis of an asparagine-linked oligosaccharide-containing calcitonin by a rat medullary thyroid carcinoma cell line. Biochemistry 1986; 25:2995-3000.
6. Cate CC, Pettengill OS, Sorenson GD. Biosynthesis of procalcitonin in small cell carcinoma of the lung. Cancer Res 1986; 46:812-8.
7. Birnbaum RS, Mahoney WC, Roos BA. Biosynthesis of calcitonin by a rat medullary thyroid carcinoma cell line. J Biol Chem 1986; 261: 699-703.
8. Nylen ES, O'NeillW, Jordan MH, et al. Serum procalcitonin as an index of inhalation injury in burns. Horm Metab Res 1992; 24:439-43.
9. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515-8.
10. Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother 2012; 67:2560-9.
11. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3:1541-54.
12. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-8.
13. Thomas L. Physiological disturbances produced by endotoxins. Annu Rev Physiol 1954; 16:467-90.
14. Ulich TR, Evo K, del Castillo J. Endotoxin induced cytokine gene expression in vivo. Am J Pathol 1989; 134:11-4.
15. Adi S, Pollock AS, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Role of monokines in the metabolic effects of endotoxins. J Clin Invest 1992; 89:1603-9.
16. Bossink A, Groeneveld J, Lambertus G. Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha-antitrypsin and lactoferrin compared with clinical variables. Clin Infect Dis 1999; 29:398-407.
17. Nijsten MW, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vitro. Crit Care Med 2000; 28:458-61.
18. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-69.
19. Level C, Chauveau P, Delmas Y, et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 2001; 16:980-6.
20. Meisner M, Schmidt J, Hüttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 2000; 26(suppl 2):212-6.
21. Dahaba AA, Rehak PH, List WF. Procacitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29:579-83.
22. Contou D, d'Ythurbide G, Messika J, et al. Description and predictive factors of infection in patients with chronic kidney disease admitted to the critical care unit. J Infect 2014; 68:105-15.
23. Herget-Rosenthal S, Klein T, Marggraf G, et al. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol 2005; 61:180-6.
24. Lavín-Gómez BA, Palomar-Fontanet R, Gago-Fraile M, et al. Inflammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial 2011; 27:33-7.
25. Herget-Rosenthal S, Marggraf G, Pietruck F, et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 2001; 16:975-9.
26. Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin: diagnostic value in systemic infection in chronic kidney disease or renal transplant patients. Int Urol Nephrol 2014; 46:461-68.
27. Sitter T, Schmidt M, Schnelder S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney disease using procalcitonin. J Nephrol 2002; 15:297-301.
28. Mesiner M. PCT-Ein neuer Parameter fur schwere infektionen und sepsis; in biochemische und klininsche aspekte. 2nd ed. Berlin, Brahms-Diagnostica, 1997; 61-77.
29. Trimarchi H, Dicugno M, Muryan A, et al. Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires) 2013; 73:411-6.
30. Mori K, Noguchi M, Sumino Y, Sato F, Mimata H. Use of procalcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin. ISRN Urol 2012; 2012:1-6.
31. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/ systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40:1250-6.
32. Montagnana M, Lippi G, Tessitore N, et al. Procalcitonin values after dialysis in closely related type of dialysis membrane. Scand J Clin Lab Invest 2009; 69:703-7.
33. Nishikura T. The clearance of procalcitonin (PCT) during continuous veno-venous hemodiafiltration (CVVHD). Intensive Care Med 1999; 25:1198-201.
34. National Kidney Foundation-Dialysis Outcomes Quality Initiative. National Kidney Foundation-Dialysis Outcome Quality Initiative clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis 1997:30(4 suppl 3):S15-66.
35. Lorton F, Veinberg F, Ielsch D, Deschenes G, Bensman A, Ulinski T. Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nepthrol 2007; 22:430-5.
36. Schmidt M, Burchardi C, Sitter T, Held E, Schiffl H. Procalcitonin in patients undergoing chronic hemodialysis. Nephron 2000; 84:187-8.
37. Guz G, Colak B, Hizel K, et al. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int 2006; 26:240-8.
38. Visvardis G, Griveas I, Fleva A, et al. Relevance of procalcitonin levels in comparison to other markers of inflammation in hemodialysis patients. Ren Fail 2005; 27:429-34.
39. Giovanella L. Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. Exp Clin Endocrinol Diabetes 2012; 120:169-70.
40. Steinbach G, Bölke E, Grünert A, Störck M, Orth K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr 2004; 116:849-53.
41. Opatrná S, Klaboch J, Opatrný K Jr, et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int 2005; 25:470-2.
42. European Renal Association European-Dialysis and Transplant Association (ERA-EDTA) report on management of renal failure in Europe. Causes of death. Nephrol Dial Transplant 1995; 10:S11-12.
43. Lacson K, Owen W. Interaction between hemodialysis adequacy and nutrition in dialysis patients. Semin Dial 1999; 12:112-9.
44. Dahaba AA, Elawady GA, Rehak PH, List WF. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 2002; 30: 269-74.
45. Caldini A, Chelazzi C, Terreni A, et al. Is procalcitonin a reliable marker of sepsis in critically ill septic patients undergoing continuous veno-venous hemofiltration with "high cut-off" membranes (HCOCVVHDF)? Clin Chem Lab Med 2013; 51:e261-3.
46. Level C, Chauveau P, Guisset O, et al. Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure. Crit Care 2003; 7:R160-6.
47. Meisner M, Hüttemann E, Lohs T, Kasakov L, Reinhart K. Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients. Shock 2001; 15:171-5.
48. MeisnerM, Hüttemann E, Lohs T, Kasakov L, Reinhart K. Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients. Eur J Anaesth 2000; 17:665-71.
49. Lu XL, Xiao ZH, Yang MY, Zhu YM. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant 2013; 28:122-9.
50. Ozturk R, Yilmaz GR, Bulut C, et al. Assessment of procalcitonin and other inflammatory markers in peritoneal dialysis-related peritonitis. Turk J Med Sci 2010; 40:199-206.
51. Lam MF, Leung JC, Lam CW, et al. Procalcitonin fails to differentiate inflammatory status or predict long-term outcomes in peritoneal dialysis-associated peritonitis. Perit Dial Int 2008; 28:377-84.
52. Yu XY, Wang Y, Zhong H, Dou QL, Song YL,Wen H. Diagnostic value of serum procalcitonin in solid organ transplant recipients: a systematic review and meta-analysis. Transplant Proc 2014; 46:26-32.
53. Lee SH, Chan RC, Wu JY, Chen HW, Chang SS, Lee CC. Diagnostic value of procalcitonin for bacterial infection in elderly patients-a systemic review and meta-analysis. Int J Clin Pract 2013; 67:1350-7.
54. Eberhard OK, Langefeld I, Kuse ER, et al. Procalcitonin in the early phase after renal transplantation-will it add to diagnostic accuracy? Clin Transplant 1998; 12:206-11.
55. Brodska H, Drabek T, Malickova K, et al. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care 2009; 13:R37.
56. Bouadma L, Luyt CE, Tubach F, et al.; PRORATA Trial Group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-74.
57. Yilmaz FM, Yilmaz G, Akay H, Duranay M, Yucel D. Evaluation of a card test for procalcitonin in continuous ambulatory peritoneal dialysis peritonitis. Ann Clin Biochem 2007; 44:482-4.